Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12517MR)

This product GTTS-WQ12517MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12517MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5931MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ8553MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ12420MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ3944MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ5281MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ7366MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ423MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ1460MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW